Monitor Genmab's upcoming earnings release for royalty revenue recognition and any guidance updates. The DARZALEX sales trajectory is a key indicator of Genmab's financial health, but this filing alone provides no comparative data or forward-looking statements.
Drug in focus
GMAB drug pipeline →DARZALEX
▲ Bullish Named in this 6-K- Impact
- Phase
- Approved (multiple FDA-approved multiple-myeloma indications); additional label-expansion Phase 3 studies completed.
- Time to market
- Already approved and on the market — DARZALEX (IV) since Nov 2015 and DARZALEX FASPRO (subcutaneous) since May 2020; label expansion for newly diagnosed multiple myeloma added ~Jan 2026.
- Next catalyst
- None dated
What to watchFor JNJ shareholders, DARZALEX is a cash-cow growth driver, not a binary, treat it as part of the Innovative Medicine growth story (with CARVYKTI, TREMFYA, SPRAVATO) that supported the FY2026 guidance raise, and watch each Genmab 6-K for quarterly DARZALEX net sales as the cleanest read on the franchise. The bigger near-term event to track is competitive: Bristol Myers' iberdomide + daratumumab + dexamethasone PDUFA landed Aug 17, 2026, and BMY's bb2121 CAR-T Phase 3 readout is pending.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 15 $29.08entry
- T+1 · 4mo ago −0.34%α +0.20% · $28.98
- T+5 · 4mo ago −0.79%α +0.19% · $28.85
- T+20 · 3mo ago +8.05%α +5.70% · $31.42
- T+60 · 6w ago +23.97%α +21.44% · $36.05
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Genmab disclosed Q2 2026 worldwide net sales of DARZALEX at USD 4,207 million, with USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. The company receives royalties on these sales from Johnson & Johnson. This is a routine quarterly sales update without comparative data or guidance, providing a top-line indicator of Genmab's primary revenue driver.
Key Facts
- Worldwide net trade sales of DARZALEX in Q2 2026 totaled USD 4,207 million.
- U.S. net sales were USD 2,435 million; rest of world net sales were USD 1,772 million.
- Genmab receives royalties on worldwide DARZALEX sales under its license with Johnson & Johnson (Janssen).
Financial Impact
DARZALEX Q2 2026 net sales of USD 4,207 million; Genmab's royalty revenue depends on these sales, but the filing does not disclose Genmab's own financials.
Risk Factors
- Heavy reliance on DARZALEX royalties for revenue.
- Potential competition from biosimilars or alternative therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000102 |
| Document: gmab_20260715x6k.htm | 0001434265-26-000102 |
| Document: 0001434265-26-000102-index-headers.html | 0001434265-26-000102 |
| Document: 0001434265-26-000102-index.html | 0001434265-26-000102 |
| Document: 0001434265-26-000102.txt | 0001434265-26-000102 |
Track record
31 reports on GMAB
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers